From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: TRX

Search articles by EPIC code

Tissue Regenix – 2022 results, is it “achieving strong commercial traction”?

Previously writing on regenerative medical device group Tissue Regenix (TRX), I noted argues distribution agreement ‘delight’. How’s that balance sheet now?. The group has now announced results for the 2022 calendar year, arguing they with it “having delivered on its strategy for growth whilst achieving strong commercial traction”. What does that actually mean financially though?


Tissue Regenix – “product launch” & “distribution agreement”, ramptastic?

Regenerative medical device company Tissue Regenix (TRX) states “following the successful launch of VNEW with ARMS Medical in September 2021, we are very pleased to be continuing our partnership and launching the VNEW Fascia Lata allograft for surgical procedures to support tissue”. So what of a share price response slightly lower to 0.575p?

Tissue Regenix – argues “delivered robust financial and operational performance”. Has it?...

Describing itself as “a leading medical devices company in the field of regenerative medicine” Tissue Regenix (TRX) has made a full-year trading update headlined “Return to double digit growth in 2021” and concluding “the company has delivered robust financial and operational performance”. Why then are the shares still below 0.50p, compared to above 1.2p in May 2020?...


Tissue Regenix – is it really “strong H1 results” & “a strong cash position” from this former Neil Woodford dog?

Tissue Regenix (TRX) has announced results for the first half of 2021 claiming “we have created a commercially focussed regenerative global medtech company in a high growth sector… encouraged by our strong H1 results” and that we “look forward to this being further built on in H2”. So why are the shares, at 0.675p, currently more than 4% lower?

Page 1 of 3 (21 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments